GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Vyhledat
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Vargatef®
Combination therapy with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
Giotrif®
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous hist
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
new_analysis_nintedanib_SSc_ILD
Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
biopharmaceuticals-in-china
Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.